| LBCTR2020074518 | OPERA2020 | A Prospective Observational study to describe the pattern and effectiveness of the utilization of different treatment options for Metastatic Renal Cell Carcinoma | A Prospective Observational study to describe the pattern and effectiveness of the utilization of different treatment options for Metastatic Renal Cell Carcinoma | Observational | Recruiting | 10/07/2020 |
| LBCTR2023115331 | BO42451 | A RANDOMIZED DOUBLE-BLIND PHASE IIA STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB AS ADJUNCT TREATMENT IN PREVENTION OF VASO-OCCLUSIVE EPISODES (VOE) IN SICKLE CELL DISEASE (SCD) | A RANDOMIZED DOUBLE-BLIND PHASE IIA STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB AS ADJUNCT TREATMENT IN PREVENTION OF VASO-OCCLUSIVE EPISODES (VOE) IN SICKLE CELL DISEASE (SCD) | Interventional | Recruiting | 06/04/2023 |
| LBCTR2019020193 | CLMB763X2202 | A randomized patient-and-physician blinded, placebo- controlled, 24-week study to assess the safety, tolerability and efficacy of LMB763 in patients with diabetic nephropathy | A randomized patient-and-physician blinded, placebo- controlled, 24-week study to assess the safety, tolerability and efficacy of LMB763 in patients with diabetic nephropathy | Interventional | Complete | 09/02/2019 |
| LBCTR2019020191 | CAIN457M2302 | A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa (SUNRISE) | A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa (SUNRISE) | Interventional | Complete | 08/02/2019 |
| LBCTR2021064791 | GBT2104-131 | A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises | A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises | Interventional | Recruiting | 05/05/2021 |
| LBCTR2021074831 | GBT2104-132 (C5361002) | A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises | GBT2104-132: A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises | Interventional | Other | 24/06/2021 |
| LBCTR2018120171 | MB02-C-02-17 | A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC) | A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC) | Interventional | Complete | 18/11/2020 |
| LBCTR2019030205 | MO40628 | A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER | A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER_ EUDRACT NUMBER: 2018-002153-30 | Interventional | Complete | 27/02/2019 |
| LBCTR2019091283 | C1701-202 | A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients with Stable Sickle Cell Disease | A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients with Stable Sickle Cell Disease | Interventional | Complete | 12/09/2019 |
| LBCTR2022105085 | MX39897 | A REGISTRY TO COLLECT CHARACTERISTICS AND OUTCOMES FROM PATIENTS WITH SOLID TUMORS PROFILED WITH A NEXT-GENERATION SEQUENCING TEST (WAYFIND-R) | A REGISTRY TO COLLECT CHARACTERISTICS AND OUTCOMES FROM PATIENTS WITH SOLID TUMORS PROFILED WITH A NEXT-GENERATION SEQUENCING TEST (WAYFIND-R) | Observational | Pending | 25/06/2022 |